MTOR and non-small cell lung carcinoma: In this study, we clearly demonstrated that mTOR inhibition renders EML4-ALK+ NSCLC cells more vulnerable to crizotinib-mediated apoptotic death, and this inhibition even re-sensitizes acquired crizotinib-resistant NSCLC cells, H3122CR1, to crizotinib.